LucentAD® Complete
A comprehensive biomarker panel for assessing Alzheimer’s pathology.
LucentAD® p-Tau 217
A highly specific test identifying Alzheimer’s pathology before symptoms progress.
*LucentAD tests are not standalone and are not FDA approved.
About the Test
The LucentAD® Complete Alzheimer’s Blood Test looks at five key indicators in your blood to help determine if changes in your brain may be related to Alzheimer’s disease. It’s designed for people who are experiencing memory or thinking problems
The test detects key biomarkers associated with Alzheimer’s disease, including:
- p-Tau 217 – Indicates tau pathology and neurofibrillary tangles
- Amyloid Beta 42/40 Ratio – Correlates with amyloid plaque burden
- Neurofilament Light Chain (NfL) – Reflects neurodegeneration
- Glial Fibrillary Acidic Protein (GFAP) – a marker of astrocytic response in AD
No, this test does not diagnose Alzheimer’s disease. It provides an algorithm score based on biomarker data that can support risk assessment and clinical decision-making in conjunction with cognitive testing and imaging.
|
|
LucentAD Complete |
PET Scan |
CSF (Spinal Tap) |
|
Sample Type |
Blood |
Imaging |
Spinal fluid |
|
Sensitivity |
90% |
88%-98%2 |
73.3%-100%4 |
|
Specificity |
90% |
80%-95%2 |
70%-92.4%4 |
|
Testing Time |
~10 minutes3 |
~60 min, start to finish3 |
~30 min-1.5 hours, start to finish |
|
Patient Burden |
Minimal |
Moderate-high |
Moderate-high |
|
Scheduling |
Immediate |
1-2 days after ordered & insurance auth3 |
1-2 weeks after ordered & insurance auth3 |
|
Recovery Time |
No |
Minimal-radioactive dye in the blood |
Yes |
Patient Selection & Clinical Use
Consider testing patients who:
- Exhibit early cognitive symptoms such as memory loss, confusion, or cognitive impairment
- Are interested in early detection and pathology assessment
- Require a non-invasive alternative to CSF or PET imaging
LucentAD Complete provides an algorithmic score based on biomarker levels, helping assess the likelihood of Alzheimer’s pathology. Interpretation should be done in the context of patient history, symptoms, and additional diagnostic tools.
If biomarkers indicate increased Alzheimer’s risk, providers may consider:
- Additional evaluation, including imaging or CSF analysis (if clinically necessary)
- Referral to neurology or memory care specialists
- Early intervention strategies, including lifestyle modifications and clinical trial opportunities
Ordering & Logistics
The test can be ordered using our paper requisitions or through our provider portal. Contact Lucent Diagnostics or visit our website to get set up.
The blood sample is collected in a standard clinical setting and processed at our Billerica, MA CLIA certified laboratory equipped with Simoa® technology for high-sensitivity biomarker detection.
Turnaround time is typically 10 business days, depending on lab processing and logistics.
Insurance & Cost Considerations
Insurance coverage varies. Some payers may cover the test for patients with cognitive symptoms, but others may not. Patients should check with their insurance providers for details.
Yes, we have a Patient Financial Assistance Program to support those who qualify.
Pricing depends on the patient’s qualifications. Contact us for specific cost details.
Scientific & Clinical Validation
The test is clinically validated and backed by research showing strong correlation with PET imaging and CSF biomarkers. The use of Simoa® technology ensures high sensitivity and specificity.
Integration Into Clinical Practice
At this time, the test is not intended for population-wide screening but is recommended for patients with cognitive concerns
Yes, the test can be used to support drug trials.
Getting Started
To integrate the LucentAD Complete into your practice:
Register as a provider with Lucent Diagnostics
Educate your team on patient selection and test interpretation
For test ordering, clinical support, or reimbursement inquiries, reach out to our team: